PMID- 37608525
OWN - NLM
STAT- MEDLINE
DCOM- 20240308
LR  - 20240308
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 23
IP  - 3
DP  - 2024 Mar
TI  - Cardiovascular toxicities following the use of tyrosine kinase inhibitors in 
      hepatocellular cancer patients: a retrospective, pharmacovigilance study.
PG  - 287-296
LID - 10.1080/14740338.2023.2251398 [doi]
AB  - BACKGROUND: Cardiac adverse events (AEs) are common in tyrosine kinase 
      inhibitors(TKIs). This study explored the cardiac AEs of TKIs through the Food 
      and Drug Administration's Adverse Event Reporting System (FAERS). METHODS: 
      Disproportionality analysis and Bayesian analysis were utilized for data mining 
      of the suspected cardiac AEs of TKIs, based on FAERS data from January 2004 to 
      December 2021. RESULTS: A total of 4708 cardiac AEs reports of sorafenib, 
      regorafenib, lenvatinib, and cabozantinib were identified. Hypertension accounts 
      for the most reported cardiac AE. Lenvatinib appears to induce cardiac failure 
      with the highest signals strength [ROR = 7.7 (3.46,17.17)]. Acute myocardial 
      infarction was detected in lenvatinib [ROR = 7.91 (5.64,11.09)] and sorafenib 
      [ROR = 2.22 (1.74, 2.84)]. Acute coronary syndrome was detected in lenvatinib 
      [ROR = 11.57 (6.84, 19.58)] and sorafenib [ROR = 2.81 (1.87,4.24)]. Atrial 
      fibrillation was detected in sorafenib [ROR = 1.82 (1.55,2.14)] and regorafenib 
      [ROR = 1.36 (1.03,1.81)]. Meanwhile, aortic dissections were detected in 
      sorafenib [ROR = 5.08 (3.31,7.8)] and regorafenib [ROR = 3.39 (1.52,7.56)]. Most 
      patients developed hypertension and cardiac failure within 30 days of initiating 
      TKI treatments. Patients taking lenvatinib had an increased incidence of 
      developing acute coronary syndrome after 180 days of treatment. CONCLUSION: 
      Analysis of FAERS data provides a precise profile on the characteristics of 
      cardiac AEs associated with different TKI regimens. Distinct monitoring and 
      appropriate management are needed in the care of TKI recipients.
FAU - Lai, Xin
AU  - Lai X
AUID- ORCID: 0009-0004-0288-3043
AD  - Department of Pharmacy, First Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Wan, Qing
AU  - Wan Q
AD  - Department of Pharmacy, First Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Jiao, Shou-Feng
AU  - Jiao SF
AD  - Department of Pharmacy, First Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Sun, Xiao-Chun
AU  - Sun XC
AD  - Department of Pharmacy, First Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Hu, Jin-Fang
AU  - Hu JF
AD  - Department of Pharmacy, First Affiliated Hospital of Nanchang University, 
      Nanchang, China.
FAU - Peng, Hong-Wei
AU  - Peng HW
AD  - Department of Pharmacy, First Affiliated Hospital of Nanchang University, 
      Nanchang, China.
LA  - eng
PT  - Journal Article
DEP - 20230829
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 24T2A1DOYB (regorafenib)
RN  - EE083865G2 (lenvatinib)
RN  - 0 (Tyrosine Kinase Inhibitors)
RN  - 9ZOQ3TZI87 (Sorafenib)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Quinolines)
SB  - IM
MH  - United States
MH  - Humans
MH  - Tyrosine Kinase Inhibitors
MH  - *Acute Coronary Syndrome
MH  - Sorafenib/adverse effects
MH  - Retrospective Studies
MH  - Bayes Theorem
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Pharmacovigilance
MH  - *Liver Neoplasms/drug therapy
MH  - *Heart Failure
MH  - *Hypertension
MH  - United States Food and Drug Administration
MH  - Adverse Drug Reaction Reporting Systems
MH  - *Phenylurea Compounds
MH  - *Pyridines
MH  - *Quinolines
OTO - NOTNLM
OT  - Cardiac adverse events
OT  - data mining
OT  - hepatocellular cancer
OT  - non-proportional analysis
OT  - tyrosine kinases inhibitors
EDAT- 2023/08/23 06:42
MHDA- 2024/03/08 06:42
CRDT- 2023/08/23 01:13
PHST- 2024/03/08 06:42 [medline]
PHST- 2023/08/23 06:42 [pubmed]
PHST- 2023/08/23 01:13 [entrez]
AID - 10.1080/14740338.2023.2251398 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2024 Mar;23(3):287-296. doi: 10.1080/14740338.2023.2251398. 
      Epub 2023 Aug 29.